Drugmaker Biovail to buy Valeant in $3.3 billion deal | 合法醫療器材資訊網

2010年6月21日—ShareholdersofBiovail,Canada'slargestpubliclyownedpharmaceuticalcompanyandmakerofsuchdrugsastheWellbutrindepressiontreatment, ...

TORONTO/BANGALORE (Reuters) - Biovail Corp BVF.TO[1] is to take over U.S-based Valeant Pharmaceuticals International VRX.N[2] in a complex deal that positions the enlarged firm to better serve the growing baby boomer market.

Biovail CEO William Wells speaks to the media after Biovails Annual General Meeting in Toronto, June 25, 2008. REUTERS/Mark Blinch

Worth roughly $3.3 billion, the deal announced early on Monday will take advantage of tax breaks and other savings to create a company that retains the Valeant name and is run by Valeant’s existing chief executive, Michael Pearson.

Shareholders of Biovail, Canada’s largest publicly owned pharmaceutical com...